Weekly Spotlight - 21.11.24

Community

We want to hear your story!

Fill in the form to share your experiences and any challenges you’ve faced living with your condition, for a chance to be featured in one of our weekly newsletters!

Latest News

Columvi Demonstrates High Response Rates in Relapsed/Refractory Patients

The article discusses the clinical trial results of the drug combination known as "Columvi" for treating relapsed or refractory mantle cell lymphoma. It highlights high response rates and safety profiles, offering promising outcomes for patients with this type of cancer. This treatment could be a significant advancement for those suffering from mantle cell lymphoma.

Bendamustine and Obinutuzumab Combo Enhances Complete Response Rates in MCL Patients

The article discusses a new treatment combination for mantle cell lymphoma, using bendamustine and obinutuzumab, which may improve complete response rates. This combination shows promise in clinical trials, offering potential benefits for patients with this type of cancer.

BTK Inhibitors Show Promise as Second-Line Treatment for Late-Relapse Patients

A study suggests that BTK inhibitors could be an effective second-line treatment for patients with mantle cell lymphoma who experience late relapse. The data show promising outcomes, indicating these inhibitors may offer a better option compared to other treatments in this specific scenario.

Managing Side Effects of Liso-Cel Treatment in MCL Patients

The article discusses managing side effects associated with the treatment liso-cel in patients with mantle cell lymphoma. Dr. Gordon explains strategies to mitigate these toxicities, ensuring patients can tolerate the treatment and benefit from its efficacy in managing the disease.